| Título |
Glucocorticoids improve high-intensity exercise performance in humans |
| Autores |
CASUSO PÉREZ, RAFAEL, Melskens, Lars , Bruhn, Thomas , Secher, Niels H. , Nordsborg, Nikolai Baastrup |
| Publicación externa |
Si |
| Medio |
EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY |
| Alcance |
Article |
| Naturaleza |
Científica |
| Cuartil JCR |
2 |
| Cuartil SJR |
1 |
| Impacto JCR |
2.187 |
| Impacto SJR |
1.179 |
| Fecha de publicacion |
01/02/2014 |
| ISI |
000331651600019 |
| DOI |
10.1007/s00421-013-2784-7 |
| Abstract |
Purpose It was investigated whether oral dexamethasone (DEX) administration improves exercise performance by reducing the initial rate of muscle fatigue development during dynamic exercise.\n Methods Using a double-blinded placebo controlled randomized crossover design, subjects ingested either 2 x 2 mg of DEX or placebo for five consecutive days. Muscle function was investigated using one-legged kicking exercise and whole body performance was evaluated using a 20-m shuttle run and a 30-m sprint test.\n Results One-legged dynamic knee-extensor exercise time to exhaustion was 29 +/- 35 % (mean +/- SD) longer (P < 0.05) in DEX compared to Placebo. Likewise, total running distance in the shuttle run test was 19 +/- 23 % longer (P < 0.05), whereas 30-m sprint performance was unaltered. During the initial 75 s of dynamic leg extensions, peak force and rate of force development determined from an electrically evoked twitch declined in a similar way in DEX and placebo. Similarly, the EMG root mean square was similar with DEX and placebo treatment.\n Conclusion Short-term dexamethasone administration increases high-intensity one-legged kicking time to exhaustion and 20-m shuttle run performance, although sprint ability and the initial loss of muscular force generating capacity are similar after DEX and placebo. |
| Palabras clave |
Muscle mass; Dexamethasone; Sport; Doping; EMG |
| Miembros de la Universidad Loyola |
|
Gestionar cookies